Evidence map›Paper›PMID 36119652›Full record

ArticlebioRxiv : the preprint server for biology2022

Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir.

Yanmei Hu, Eric M Lewandowski, Haozhou Tan, Xiaoming Zhang, Ryan T Morgan, Xiujun Zhang, Lian M C Jacobs, Shane G Butler, Maura V Gongora, John Choy and 3 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 93 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Yanmei HuDepartment of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, NJ, 08854, United States.
Eric M LewandowskiDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, 33612, United States.
Haozhou TanDepartment of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, NJ, 08854, United States.
Xiaoming ZhangDepartment Physiological Sciences, College of Veterinary Medicine, Oklahoma State University, Stillwater, OK, 74078, United States.
Ryan T MorganDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, 33612, United States.
Xiujun ZhangDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, 33612, United States.
Lian M C JacobsDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, 33612, United States.
Shane G ButlerDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, 33612, United States.
Maura V GongoraDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, 33612, United States.
John ChoyDepartment Biology, School of Arts and Sciences, the Catholic University of America, Washington DC, 20064, United States.
Xufang DengDepartment Physiological Sciences, College of Veterinary Medicine, Oklahoma State University, Stillwater, OK, 74078, United States.
Yu ChenDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, 33612, United States.
Jun WangDepartment of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, NJ, 08854, United States.
University of South Florida · USOklahoma State University · USRutgers, The State University of New Jersey · USCatholic University of America · US

Funding

Development of dual inhibitors targeting the viral main protease and the host cathepsin L as SARS-CoV-2 antiviralsR01AI158775 · NIAID · UNIVERSITY OF ARIZONA · PI Jun Wang · 2021 to 2026
$3.6M
Drug target validation of the enterovirus D68 2A proteaseR01AI157046 · NIAID · UNIVERSITY OF ARIZONA · PI WANG, JUN · 2020 to 2024
$3.4M
High Throughput Screening of Inhibitors Targeting the Enterovirus A71 and D68 2A ProteasesR01AI147325 · NIAID · UNIVERSITY OF ARIZONA · PI WANG, JUN · 2019 to 2022
$1.7M
NIAID NIH HHS R01 AI147325NIAID NIH HHS R01 AI157046NIAID NIH HHS R01 AI158775
6 · The paper itself

Abstract

The SARS-CoV-2 main protease (M One Sentence Summary: Paxlovid resistant SARS-CoV-2 viruses with mutations in the main protease have been identified from clinical isolates.

Identifiers

PMID36119652
PMCPMC9479041
OpenAlexW4283730960

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.